GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET FORECAST 2022-2030


TABLE OF CONTENTS

 

1.     RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES

1.2. SCOPE OF STUDY

1.3. METHODOLOGY

1.4. ASSUMPTIONS & LIMITATIONS

2.     EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES

2.2. MARKET OVERVIEW

3.     MARKET DYNAMICS

3.1. PARENT MARKET ANALYSIS

3.2. KEY DRIVERS

3.2.1.   GROWING GERIATRIC POPULATION

3.2.2.   RISING PERVASIVENESS OF ALZHEIMER’S DISEASE

3.2.3.   EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES

3.2.4.   INCREASING PIPELINE DRUGS

3.3. KEY RESTRAINTS

3.3.1.   FAILURE OF THE LATE-STAGE DRUGS

3.3.2.   STRINGENT GOVERNMENT REGULATIONS

3.3.3.   LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4.     KEY ANALYTICS

4.1. TIMELINE OF ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.2. PHASES AND STERNNESS OF ALZHEIMER’S DISEASE

4.3. IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

4.4. KEY MARKET TRENDS

4.5. PORTER’S FIVE FORCES ANALYSIS

4.5.1.   BUYERS POWER

4.5.2.   SUPPLIERS POWER

4.5.3.   SUBSTITUTION

4.5.4.   NEW ENTRANTS

4.5.5.   INDUSTRY RIVALRY

4.6. KEY BUYING CRITERIA

4.7. SUPPLY CHAIN ANALYSIS

4.8. OPPORTUNITY MATRIX

4.9. VENDOR LANDSCAPE

5.     MARKET BY THERAPEUTICS & DIAGNOSTICS

5.1. THERAPEUTICS

5.1.1.   DRUGS

5.1.1.1.        MARKETED DRUGS

5.1.1.2.        PIPELINE DRUGS

5.1.2.   DISEASE STAGE

5.1.2.1.        LATE-STAGE: SEVERE AD

5.1.2.2.        EARLY/MIDDLE STAGE: MILD TO MODERATE AD

5.1.2.3.        PRODROMAL STAGE

5.1.3.   GENERIC & BRANDED

5.1.3.1.        BRANDED

5.1.3.2.        GENERIC

5.2. DIAGNOSTICS

5.2.1.   LUMBAR PUNCTURE TEST

5.2.2.   POSITRON EMISSION TOMOGRAPHY

5.2.3.   ELECTROENCEPHALOGRAPHY

5.2.4.   MAGNETIC RESONANCE IMAGING

5.2.5.   COMPUTED TOMOGRAPHY

5.2.6.   BLOOD TEST

5.2.7.   OTHER DIAGNOSTICS

6.     GEOGRAPHICAL ANALYSIS

6.1. NORTH AMERICA

6.1.1.   MARKET SIZE & ESTIMATES

6.1.2.   KEY GROWTH ENABLERS

6.1.3.   KEY CHALLENGES

6.1.4.   KEY PLAYERS

6.1.5.   COUNTRY ANALYSIS

6.1.5.1.        UNITED STATES

6.1.5.2.        CANADA

6.2. EUROPE

6.2.1.   MARKET SIZE & ESTIMATES

6.2.2.   KEY GROWTH ENABLERS

6.2.3.   KEY CHALLENGES

6.2.4.   KEY PLAYERS

6.2.5.   COUNTRY ANALYSIS

6.2.5.1.        UNITED KINGDOM

6.2.5.2.        GERMANY

6.2.5.3.        FRANCE

6.2.5.4.        ITALY

6.2.5.5.        BELGIUM

6.2.5.6.        POLAND

6.2.5.7.        REST OF EUROPE

6.3. ASIA-PACIFIC

6.3.1.   MARKET SIZE & ESTIMATES

6.3.2.   KEY GROWTH ENABLERS

6.3.3.   KEY CHALLENGES

6.3.4.   KEY PLAYERS

6.3.5.   COUNTRY ANALYSIS

6.3.5.1.        CHINA

6.3.5.2.        JAPAN

6.3.5.3.        INDIA

6.3.5.4.        SOUTH KOREA

6.3.5.5.        INDONESIA

6.3.5.6.        THAILAND

6.3.5.7.        VIETNAM

6.3.5.8.        AUSTRALIA & NEW ZEALAND

6.3.5.9.        REST OF ASIA-PACIFIC

6.4. REST OF WORLD

6.4.1.   MARKET SIZE & ESTIMATES

6.4.2.   KEY GROWTH ENABLERS

6.4.3.   KEY CHALLENGES

6.4.4.   KEY PLAYERS

6.4.5.   REGIONAL ANALYSIS

6.4.5.1.        LATIN AMERICA

6.4.5.2.        MIDDLE EAST & AFRICA

7.     COMPETITIVE LANDSCAPE

7.1. KEY STRATEGIC DEVELOPMENTS

7.1.1.   MERGERS & ACQUISITIONS

7.1.2.   PRODUCT LAUNCHES & DEVELOPMENTS

7.1.3.   PARTNERSHIPS & AGREEMENTS

7.1.4.   BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

7.2. COMPANY PROFILES

7.2.1.   ALLERGAN PLC (ACQUIRED BY ABBVIE)

7.2.2.   AMARANTUS BIOSCIENCE HOLDINGS INC

7.2.3.   BAXTER INTERNATIONAL INC

7.2.4.   BIOGEN INC

7.2.5.   COGNOPTIX INC

7.2.6.   EISAI CO LTD

7.2.7.   ELI LILLY & COMPANY

7.2.8.   F HOFFMANN-LA ROCHE

7.2.9.   GE HEALTHCARE

7.2.10.                    JOHNSON & JOHNSON

7.2.11.                    LUPIN LIMITED

7.2.12.                    MERCK & CO INC

7.2.13.                    NOVARTIS AG

7.2.14.                    PFIZER INC

7.2.15.                    SIEMENS HEALTHINEERS AG

7.2.16.                    SUN PHARMACEUTICALS INDUSTRIES LTD

7.2.17.                    TEVA PHARMACEUTICAL INDUSTRIES LIMITED

7.2.18.                    ZYDUS CADILA

 

LIST OF TABLES

 

TABLE 1: MARKET SNAPSHOT - ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS

TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS & DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 6: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 14: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 15: GLOBAL LATE-STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 28: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 29: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 40: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 41: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 42: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 43: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 44: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 45: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 46: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 47: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 48: LEADING PLAYERS OPERATING IN NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 49: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 50: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 51: LEADING PLAYERS OPERATING IN EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 52: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 53: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 54: LEADING PLAYERS OPERATING IN ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 55: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 56: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 57: LEADING PLAYERS OPERATING IN REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET

TABLE 58: LIST OF MERGERS & ACQUISITIONS

TABLE 59: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 60: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 61: LIST OF BUSINESS EXPANSIONS, ANNOUNCEMENTS, & DIVESTITURES

 

LIST OF FIGURES

 

FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE

FIGURE 2: KEY MARKET TRENDS

FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

FIGURE 4: KEY BUYING CRITERIA

FIGURE 5: SUPPLY CHAIN ANALYSIS

FIGURE 6: OPPORTUNITY MATRIX

FIGURE 7: VENDOR LANDSCAPE

FIGURE 8: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY THERAPEUTICS & DIAGNOSTICS, IN 2021

FIGURE 9: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY THERAPEUTICS, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DRUGS, IN 2021

FIGURE 11: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2022-2030 (IN $ MILLION)

FIGURE 13: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY DISEASE STAGE, IN 2021

FIGURE 14: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE-STAGE: SEVERE AD, 2022-2030 (IN $ MILLION)

FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2022-2030 (IN $ MILLION)

FIGURE 17: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, GROWTH POTENTIAL, BY GENERIC & BRANDED, IN 2021

FIGURE 18: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2030 (IN $ MILLION)

FIGURE 20: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY DIAGNOSTICS, IN 2021

FIGURE 22: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 24: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2022-2030 (IN $ MILLION)

FIGURE 26: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2022-2030 (IN $ MILLION)

FIGURE 27: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2030 (IN $ MILLION)

FIGURE 28: GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2022-2030 (IN $ MILLION)

FIGURE 29: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: CANADA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 33: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: ITALY ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: POLAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 39: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 41: CHINA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: INDIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 46: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 48: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: REST OF ASIA-PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 50: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 51: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 52: MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS & DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

 

KEY FINDINGS

 

The global Alzheimer’s disease therapeutics & diagnostics market is anticipated to grow at a 6.61% CAGR during the estimation period between 2022 to 2030. The market growth is accelerated by the rise in the pervasiveness of Alzheimer’s disease, emerging novel diagnostic technologies, and the increasing number of pipeline drugs.

 

Get more Insights into the Global Alzheimer’s Disease Therapeutics & Diagnostics Market:

https://inkwoodresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostics-market/

 

MARKET INSIGHTS

Alzheimer’s is a neurodegenerative disease characterized by chronic inflammation and accumulation of beta-amyloid peptides. The elderly usually suffer from Alzheimer’s disease, which gradually damages their thinking skills and memory, eventually destroying their ability to perform the simplest daily tasks. Alzheimer’s disease is the major reason for dementia among the older population. Therefore, the rising geriatric population is a key driver for the global Alzheimer’s disease therapeutics and diagnostics market.

Several novel diagnostics technologies have been discovered for Alzheimer’s disease (AD), including the invention that identifies mutated proteins in subcellular compartments. This invention describes these mutations that lead to the redistribution of crucial cellular organelles.

Furthermore, alteration of organelles distribution can be a powerful diagnostic tool, an assay to screen novel therapeutic compounds for Alzheimer’s disease. This technology’s advantage includes identifying mutated proteins, which are directly involved in the genesis of AD. Thus, there is potential for providing a superior AD diagnosis compared to current diagnostic tests.

REGIONAL INSIGHTS

The global Alzheimer’s disease therapeutics & diagnostics market assessment entails the analysis of Europe, Asia-Pacific, North America, and Rest of World. The Asia-Pacific region is anticipated to propel with the highest CAGR by 2030, owing to the rapidly increasing geriatric population and government initiative to develop medicines to cure AD.

COMPETITIVE INSIGHTS

The competition in the global market is significantly high owing to the presence of generic medicines. Furthermore, strong competition exists among the key players in developing new diagnostics methodologies and treatments. However, the industry is observing meaningful strategic partnerships to enhance market presence.

Some important global players include Merck & Co Inc, Cognoptix Inc, Eli Lilly & Company, Johnson & Johnson, etc.

Our report offerings include:

·       Explore key findings of the overall market

·       Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

·       Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

·       Market Segmentation caters to a thorough assessment of key segments with their market estimations

·       Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

·       Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

·       Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

·       Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

 

SEGMENTATION

1.    ALLERGAN PLC (ACQUIRED BY ABBVIE)

2.    AMARANTUS BIOSCIENCE HOLDINGS INC

3.    BAXTER INTERNATIONAL INC

4.    BIOGEN INC

5.    COGNOPTIX INC

6.    EISAI CO LTD

7.    ELI LILLY & COMPANY

8.    F HOFFMANN-LA ROCHE

9.    GE HEALTHCARE

10.          JOHNSON & JOHNSON

11.          LUPIN LIMITED

12.          MERCK & CO INC

13.          NOVARTIS AG

14.          PFIZER INC

15.          SIEMENS HEALTHINEERS AG

16.          SUN PHARMACEUTICALS INDUSTRIES LTD

17.          TEVA PHARMACEUTICAL INDUSTRIES LIMITED

18.          ZYDUS CADILA

 

Comments

Post a Comment

Popular posts from this blog

High Voltage Cable Market: Major End-Users Augment Demands

Image
  High voltage cables (HVCs) are the backbone of electrical infrastructure globally. From their use in commercial and residential infrastructures to industrial end uses in mining, oil & gas factories, power & utilities, etc., HVCs are crucial supplements to the growth of the power sector. Besides, urbanization and industrialization globally are increasing the demand for electric power. Therefore, the surging power demand is expected to result in more power generation and transmission, thereby propelling the requirement for high voltage cables. Inkwood Research predicts that the global high voltage cable market is set to surge with a 5.12% CAGR during the forecast period 2023-2032 .   High Voltage Cable Market: Major End Uses HVCs are extensively utilized for high voltage electric power transmission. Equipped with multiple conductors, structural elements of protective jackets, and insulators, they are designed to transmit electricity efficiently without long-ra...
Read more

UAV Battery Market: Military & Commercial Applications direct Growth

Image
  Unmanned aerial vehicles (UAVs) or automated drones fly for long periods at a controlled speed and height and have a role in many aspects of aviation. They are used in various functions, ranging from food delivery, filming, photography, climate change monitoring, and search operations after natural disasters. With the growing geo-political tension among major countries, UAVs have gained massive demand. This is because drones are used by the military worldwide for surveillance, reconnaissance, and targeted attacks. These devices operate wirelessly, creating a huge requirement for UAV batteries for optimal use. Accordingly, as per our research, the   global UAV battery market   is estimated to generate a whopping   $17.7 billion   in revenue, with a   16.32% CAGR   during the forecast years,   2022-2030 .   UAV Battery: Growing Military Applications Militaries need UAVs for training in combat situations and ISR (intelligence, surveillance, an...
Read more

X-Ray Tube Market: Trending Applications & Novel Developments

Image
 X-ray tube, also known as a Roentgen tube, functions as a specific energy converter that receives electrical energy and converts it into heat (99%) and x-radiation (1%). The primary function of an X-ray tube is to create x-ray photons from electric energy transmitted by the x-ray generator. As per Inkwood Research, the global X-ray tube market is forecasted to rise with a CAGR of 3.81% during the projected years of 2022 to 2030 . Their widespread usage across applications, such as material and structure analysis, CT scanners, X-ray crystallography, and airport luggage scanners, among others, play an essential role in surging the demand and adoption of X-ray tubes worldwide.   X-Ray – An Incredible Contribution to Human Health The discovery of the X-ray in 1895 provided physicians with an effective, non-surgical tool to analyze the inside of the human body. Moreover, following the development of the ‘Coolidge tube’ in 1913, which continues to remain the model that...
Read more